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Abstract 37 
Context: Adrenocortical carcinoma (ACC) has a heterogeneous prognosis and current medical 38 
therapies have limited efficacy in its advanced stages. Genome-wide multi-omics-studies identified 39 
molecular patterns associated with clinical outcome.  40 
Objective: Here, we aimed at identifying a molecular signature useful for both personalized 41 
prognostic stratification and druggable targets, using methods applicable in clinical routine.  42 
Design: 117 tumor samples from 107 ACC patients were analyzed. Targeted next-generation 43 
sequencing of 160 genes and pyrosequencing of 4 genes were applied to formalin-fixed paraffin-44 
embedded (FFPE) specimens to detect point mutations, copy number alterations and promoter region 45 
methylation. Molecular results were combined with clinical/histopathological parameters (tumor stage, 46 
age, symptoms, resection status, and Ki67) to predict progression-free survival (PFS).  47 
Results: In addition to known driver mutations, we detected recurrent alterations in genes not 48 
previously associated with ACC (e.g. NOTCH1, CIC, KDM6A, BRCA1, BRCA2). Best prediction of 49 
PFS was obtained integrating molecular results (>1 somatic mutation, alterations in Wnt/β-catenin and 50 
p53 pathways, high methylation pattern) and clinical/histopathological parameters into a combined 51 
score (P<0.0001, chi-square 68.6). Accuracy of prediction for early disease progress was 83.3% (area 52 
under the ROC curve: 0.872, 0.80-0.94). Furthermore, 17 potentially targetable alterations were found 53 
in 64 patients (e.g. in CDK4, NOTCH1, NF1, MDM2, EGFR and in DNA repair system).  54 
Conclusions: This study demonstrates that molecular profiling of FFPE tumor samples improves 55 
prognostication of ACC beyond clinical/histopathological parameters and identifies new potential drug 56 
targets. These findings pave the way to precision medicine in this rare disease.  57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
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Introduction  65 
Adrenocortical carcinoma (ACC) is a rare tumor with a generally poor, but heterogeneous prognosis 66 
(5-year survival rate ranging from 13% to 80% [1 2]). Tumor stage according to the ENSAT 67 
(European Network for the Study of Adrenocortical Tumors) classification, which has now been used 68 
also by the American Joint Committee on Cancer (AJCC) TNM (tumor, nodes, metastasized) 69 
classification system (Supplemental Table 1 [3], https://www.cancer.org/cancer/adrenal-70 
cancer/detection-diagnosis-staging/staging.html), is one of the most relevant prognostic factors [1]. 71 
However, about 10% of patients with metastatic disease at diagnosis are still alive after 10 years and 72 
more than 20% of patients with tumor stage I-III die within the first three years [1]. Resection (R) 73 
status of the primary tumor [4 5] and Ki67 index [6] represent additional prognostic factors. A recent 74 
study also proposed a combination of clinical/histopathological parameters (i.e. tumor grade, R status, 75 
age, symptoms=GRAS score) to improve prognostication in patients with advanced ACC [7].  76 
Genome-wide studies have identified molecular patterns associated with clinical outcome [8 77 
9]. Among these, a specific gene expression pattern (i.e. high BUB1B-PINK1 levels) [8 10], specific 78 
copy number (CN) alteration [9] and CpG islands methylation patterns [8 11] have been associated 79 
with a poor prognosis. However, these studies have been performed on fresh-frozen tumor samples 80 
that are difficult to collect in routine clinical settings. Moreover, cost-intensive genome-wide 81 
technologies and complex bioinformatics workup were required, which precludes the adoption of the 82 
proposed prognostic biomarkers in clinical practice.  83 
At present, few effective pharmacological therapies are available for ACC[12]. Mitotane 84 
(Lysodren, Bristol-Myers Squibb, Princeton, New Jersey, USA) is the only approved drug, but an 85 
objective response is observed in only ~20% of cases and treatment is limited by severe adverse 86 
reactions [13 14]. Even combined therapies of mitotane and cytotoxic chemotherapies, like etoposide-87 
doxorubicin-cisplatin (EDP) [15], streptozotocin [15] and gemcitabine plus capecitabin [16 17], 88 
exhibit response rates <25%. Although some studies provided some promising insights into potential 89 
pharmacological targets [18-20], effective targeted therapies have not been identified yet [2 21].  90 
The main aim of the present study was to identify a molecular tumor signature for a prognostic 91 
classification of ACC patients that may be easily transferred into clinical practice. To this end, we 92 
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used 117 standard formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens to investigate the 93 
prognostic power of both previously proposed or new molecular markers and potential drug targets, 94 
which we evaluated by targeted next-generation sequencing (NGS). 95 
 96 
Patients and Methods 97 
Study protocol: This is a single-center retrospective study designed and conducted in accordance with 98 
the Declaration of Helsinki. We followed the recommendations for tumor prognostic markers studies 99 
reported in REMARK [22]. Moreover, we searched for known drug targets using the OncoKB website 100 
(http://oncokb.org/#/ [23]). The study protocol was approved by local ethics committee (#88/11) and 101 
written informed consent was obtained from all subjects prior to study enrollment. 102 
 103 
Patient cohort and clinical data: 107 patients were selected for the study. Inclusion criteria were 104 
histologically confirmed diagnosis of ACC and availability of FFPE tumor specimens collected 105 
between 2002 and 2016 and corresponding blood samples. Initial clinical/histopathological parameters 106 
and follow up data were collected through the ENSAT registry (https://registry.ensat.org//) (Table 1).  107 
A modified version of the GRAS classification [7] (mGRAS score) was used to merge 108 
prognostically relevant clinical/histopathological data: tumor stage (ENSAT 1-2=0 points, 3=1 point, 109 
4=2 points), grading (Ki67 proliferation index 0-9=0 points, 10-19=1 point, ≥20=2 points), resection 110 
status (R0=0 points, RX=1 point, R1=2 points, R2=3 points), age (< 50 years=0 points, ≥50 years=1 111 
point) and symptoms due to steroid autonomous secretion or tumor mass (no=0 points, yes=1 point).  112 
Progression-free survival (PFS) was the major outcome being defined as the time from tumor 113 
resection (primary surgery) to first radiological evidence of disease relapse or disease-related death.  114 
 115 
Material collection and DNA isolation: The final series included 117 FFPE samples (89 primary 116 
tumors, 10 local recurrences and 18 distant metastases). In 10 cases, tumor tissues were available from 117 
consecutive surgeries of the same patients (7 with primary+metastasis, one with primary+local 118 
recurrence, one with local recurrence+metastasis, one with two metastases). For survival analyses only 119 
the chronologically first sample of a patient was used (either primary tumor or local 120 
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recurrence/metastasis). The tumor cell content in each FFPE slide was assessed by hematoxylin-eosin 121 
staining and reached a high fraction (median 90%, range 60-95%). DNA was isolated from tumors 122 
with the GeneRead DNA FFPE Kit (Qiagen, Hilden, Germany) and from peripheral blood with the 123 
NucleoSpin Blood L Kit (Macherey-Nagel, Bethlehem, PA, USA) according to the manufacturer’s 124 
instructions. Qualitative and quantitative evaluation of DNA fragmentation was assessed by the 125 
GeneRead DNA QuantiMIZE Assay Kit (384) (Qiagen). qPCRs were performed with a SYBRGreen 126 
mix according to the manufacturer’s protocol and measured with a ViiA7 Real-Time PCR (RT-PCR) 127 
System (Thermo Fisher Scientific, Manassas, VA, USA). Data were analyzed with QuantStudio™ 128 
RT-PCR Software (Applied Biosystems, Foster City, CA, USA). The quality of all DNA samples was 129 
calculated with GeneRead DNA QuantiMIZE_384_DataAnalysis (Qiagen) in comparison to a control 130 
DNA included in the kit. Only DNA with a QC Score (indicator of sample damage/fragmentation) 131 
≤0.04 was sequenced. 132 
 133 
Targeted DNA sequencing: Tumor and leukocyte DNAs were enriched with the GeneRead DNAseq 134 
Human Comprehensive Cancer Panel V2 and GeneRead DNAseq Panel PCR Kit V2 (both Qiagen), 135 
according to the manufacturer’s protocol. This panel includes coding regions of 160 genes (7951 136 
amplicons and 744835 bases of target regions), many of them known or suspected to be involved in 137 
adrenocortical tumorigenesis or known drug targets. NGS was performed on a NextSeq500 with 138 
NextSeq Mid Output Reagent Kit V2 and 150bp paired end reads (Illumina Inc, San Diego, CA, 139 
USA). Raw data were aligned and analyzed with GensearchNGS (Phenosystems S.A., Belgium). For 140 
detection of somatic point mutations and small insertions and deletions (small Indels) in tumor 141 
samples the called variants were filtered as followed: coverage >100; exon distance <21; frequency of 142 
appearance >0.1; Minor Allele Frequency (MAF) <0.02; variant balance >0. Variants found also in the 143 
matched blood samples were excluded. Intronic and synonymous variants have been considered for 144 
calculating Tumor Mutational Burden (TMB) but not for further analysis, except of those with a 145 
predicted influence on splice sites. 146 
Impact on splicing for intronic and synonymous variants was analyzed with Alamut software 147 
(Interactive Biosoftware, Rouen, France) using five prediction algorithms: SpliceSiteFinder-like, 148 
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MaxEntScan [24], NNSPLICE [25], GeneSplicer [26] and Human Splicing Finder [27]. All other 149 
variants were evaluated for predicted pathogenicity by Polymorphism Phenotyping v2 algorithm tool 150 
(PolyPhen-2) (http://genetics.bwh.harvard.edu/pph2) [28], SIFT (Sorting Tolerant From Intolerant) 151 
algorithm (http://sift.jcvi.org/index.html) and MutationTaster (http://www.mutationtaster.org/) [29]. 152 
The Catalogue Of Somatic Mutations In Cancer (COSMIC) was used as a reference of cancer-related 153 
somatic variants (http://cancer.sanger.ac.uk/cosmic). InterVar was used as an additional tool for the 154 
interpretation of variants [30]. 155 
ZNRF3, which was previously reported to be involved in the pathogenesis of ACC [8 9 31], was 156 
evaluated separately by direct Sanger sequencing. PCR primers for the coding region of ZNRF3, 157 
except exon 1, were designed with Primer3 (version 4.0.0) software [32] (Supplemental Table 2 [3]). 158 
Sequencing data were generated with an ABI 3730 or an ABI 3130xl capillary sequencer under 159 
standard conditions and analyzed with Gensearch (Phenosystems S.A.). 160 
TMB was calculated by summing up all detected somatic variants and dividing this number by the size 161 
of the target region. Values are specified in variations per megabase (Mb). 162 
To analyze CNAs we used a combination of two different approaches: the CNV analysis tool from 163 
GensearchNGS and an in-house pipeline. Single CN gains or losses have been identified by comparing 164 
CN of matched tumor and blood samples. With GensearchNGS a fold change (FC) of 1 was 165 
considered as “normal”. Hence genes with all amplicons having a FC between 1.25 and 1.75 were 166 
considered as “heterozygous duplicated” and as “homozygous duplicated” with a FC >1.75. Genes 167 
were considered as deleted when all amplicons showed a FC <0.75. For the second approach an initial 168 
quality assessment was performed using FastQC, v0.11.3 169 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Adapters and low quality reads were 170 
trimmed using TrimGalore, v0.4.0 (http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) 171 
powered by Cutadapt, v1.8 (https://cutadapt.readthedocs.io/en/stable/). The reads were aligned against 172 
the UCSC hg19 human reference genome with BWA mem, v0.7.12 (http://bio-bwa.sourceforge.net/) 173 
using default parameters [33]. Sorted BAM-files were created using Picard v1.125 174 
(http://broadinstitute.github.io/picard) and indexed using SAMtools v1.3 (samtools.sourceforge.net/) 175 
[34]. Local realignment around Indels was executed with GATK, v3.5 176 
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(https://software.broadinstitute.org/gatk/) [35]. For CNV calling the number of reads of each amplicon 177 
was determined using the multiBamCov-Tool in the BEDTools suite, v2.26.0 178 
(bedtools.readthedocs.io/) [36]. Only markers covered with an average of at least 200 reads in control 179 
samples in the respective panel were considered. For normalization, the reads for each amplicon were 180 
divided by the total number of reads for each sample. Log2 FC was calculated for each amplicon 181 
passing QC using the corresponding amplicon in the matched control. A gene was considered 182 
amplified or deleted if at least 80% of all markers in a tumor covering the gene were amplified or 183 
deleted at least 1.5-fold. In both approaches, CNAs were only investigated for genes covered by at 184 
least 6 probes. Only CN alterations detected with both approaches were considered. 185 
 186 
Targeted DNA methylation analysis: Bisulfite pyrosequencing was used for quantitative methylation 187 
analysis of four tumor suppressor genes PAX5, PAX6, PYCARD and GSTP1 that have been 188 
demonstrated to play a significant prognostic role in ACC [11]. 500 ng of DNA from tumor and 189 
matched blood samples was used to perform bisulfite conversion and cleanup of converted DNA with 190 
the EpiTect®Fast 96 DNA Bisulfite Kit (Qiagen) according to the manufacturer’s protocol. Target 191 
regions of the assays were selected to include the regions accessible with the MLPA ME002 tumor 192 
suppressor-2 probe mix (MRC-Holland, Amsterdam, The Netherlands) (Supplemental Figure 1 [3]). 193 
PCR and sequencing primers were designed with PyroMark Assay Design 2.0 software (Qiagen) 194 
(Supplemental Table 3 [3]). Bisulfite-treated DNA was amplified in 25µl reactions containing 2.5µl 195 
10xPCR buffer with 20mM MgCl2, 0.5µl 10mM dNTP mix, 1.0µl (10pmol) of each forward and 196 
reverse Primer, 0.2µl FastStart Taq DNA Polymerase (5U/µl), 18.8µl PCR-grade H2O and 1µl 197 
bisulfite-converted DNA. PCR was carried out with an initial denaturation step at 95°C for 5 min, 198 
followed by 45 cycles 95°C for 30 seconds, primer-specific annealing temperature (58°C for PAX5 199 
and PYCARD, 59°C for PAX6, and 60°C for GSTP1) for 30 seconds and elongation at 72°C for 30 200 
seconds and a final extension step at 72°C for 7 min. Bisulfite pyrosequencing was performed on a 201 
PyroMark Q96 MD Pyrosequencing System with the PyroMark Gold Q96 CDT Reagents Kit 202 
(Qiagen). Pyro Q-CpG software (Biotage, Uppsala, Sweden) was used for data analysis. 203 
 204 
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FISH analysis: To validate CDK4 CN gains, we investigated 6 representative 2µm-thick FFPE slides 205 
by FISH analysis (two samples with “homozygous” CDK4 amplification, two with “heterozygous” 206 
CDK4 amplification and two with normal CDK4 allele status at NGS). CDK4 gene amplification was 207 
visualized through hybridization of a Zytolight SPEC CDK4/CEN12 Dual Color Probe (ZytoVision 208 
GmbH, Germany) (D12Z3) according to the manufacturer’s recommendation. At least 200 non-209 
overlapping nuclei per sample were evaluated by fluorescence microscopy (Zeiss Axioskop, Jena, 210 
Germany) using the appropriate filter sets. Only nuclei with a distinct nuclear border showing clear 211 
hybridization signals were evaluated. CDK4 gene was considered heterozygous amplified when the 212 
FISH signal ratio of CDK4/CEN12 was between 1.0 and 2.0 or homozygous amplified when the ratio 213 
was ≥2.0. Ratios may nevertheless differ when gains affect whole chromosome 12. 214 
 215 
Targeted gene expression analysis: The mRNA expression of BUB1B and PINK1 was evaluated by 216 
quantitative real-time RT-PCR only in samples with high quality RNA and cDNA (n=38). All baseline 217 
clinical/histopathological characteristics as well as follow up data of this subgroup of patients did not 218 
differ from those of the entire series. RNA was isolated from tumors by miRNeasy FFPE (Qiagen). 219 
High RNA quality was tested using an Agilent 2100 Bioanalyzer (RIN >7.5). RNA was reverse 220 
transcribed by the Quantitec Reverse Trascription Kit (Qiagen). A quantitative RT-PCR for -actin 221 
and GAPDH was performed and only samples with cycle threshold of <35 were included from further 222 
analysis (n=38). The expression of BUB1B and PINK1 was evaluated by qRT-PCR using Taqman® 223 
BUB1B (Hs01084828_m1) and PINK1 (Hs00260868_m1) probes with expressed -actin 224 
(Hs9999903_m1) as reference (Applied Biosystems, Darmstadt, Germany). Each PCR reaction was 225 
done with 40 ng cDNA and each analysis was performed in duplicate. Transcript levels were 226 
determined using the TaqMan Gene Expression Master Mix (Applied Biosystems), the CFX96 real-227 
time thermocycler (Biorad, Hercules, CA, USA), and the Bio-Rad CFX Manager 2.0 software. 228 
Cycling conditions were 95 °C for three min followed by 40 cycles of 95 °C for 30 sec, 60 °C for 30 229 
sec, and 72 °C for 30 sec. The ∆CT method was applied for normalization of gene expression levels to 230 
those of -actin. The ΔCT(BUB1B)−ΔCT(PINK1) expression was then calculated [10]. Statistical 231 
analysis with different cut-off values was performed. The best cut-off value for a high BUB1B-PINK1 232 
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differential expression was 6.3, which was already previously suggested by Bertherat and colleagues 233 
[10]. 234 
 235 
Statistical analysis: A Fisher’s exact or Chi-square test was used to investigate dichotomic variables, 236 
while a two-sided t test (or Mann-Whitney non-parametric test) was used to compare two groups of 237 
continuous variables as appropriate. A non-parametric Kruskal-Wallis test, followed by Bonferroni 238 
post-hoc test, was used for comparison among several groups for non-normal distributed variables. 239 
Correlations and 95% confidence intervals (95%CI) between different parameters were evaluated by 240 
linear regression analysis. Survival curves were obtained by Kaplan-Meier estimates and the 241 
differences between two or more curves were assessed by the log-rank (Mantel-Cox) test. Multivariate 242 
regression analysis was performed by Cox proportional hazard regression model to identify those 243 
factors that might independently influence survival. 244 
To assess and compare the prognostic accurateness and performance of different markers or scores we 245 
used two approaches: 1) We utilized the chi-square (log-rank) values (deviance chi-square test) to 246 
determine the goodness-of-fit statistic of the regression model, representing a surrogate of a 247 
Likelihood Ratio Test. 2) We calculated sensitivity, specificity and accuracy of different models 248 
categorizing patients with or without disease recurrence/progress within 24 months from primary 249 
surgery as affected/non affected. Finally, we considered the area under the receiving operating 250 
characteristics (ROC) curve and 95% confidence interval for predicted probability of disease progress 251 
within 24 months from primary surgery. 252 
Statistical analyses were made using GraphPad Prism (version 6.0, La Jolla, CA, USA) and SPSS 253 
Software (version 23, SPSS Inc., Chicago, IL, USA). P values <0.05 were considered as statistically 254 
significant. 255 
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Results 256 
Targeted molecular analysis of ACC: overview 257 
The clinical and histopathological characteristics of the 107 patients selected for the study are shown 258 
in the Table 1 (see also Patients and Methods).  259 
By performing targeted NGS in 117 ACC samples, we found a median TMB of 1.3/Mb (range: 0-260 
22,8/Mb). Altogether, we found 237 somatic genetic variants (SNVs and small Indels). The complete 261 
list of alterations and their characteristics is shown in Supplemental Data [3]. Considering the 10 262 
cases with FFPE samples from consecutive surgical interventions, most variants in driver genes were 263 
conserved in samples obtained from same patient (Supplemental Figure 2 [3]). Thus, we considered 264 
only the first available sample from each of the 107 ACC patients. Among them, 30 presented no 265 
mutations, 25 one mutation and 52 at least two mutations (median per sample: 1, range: 0-14, ≥5 266 
mutations in 13 cases). Overall, 215 protein-altering somatic variations were found, affecting 69/161 267 
evaluated genes. Among the affected genes, 40 were mutated in at least two samples and 17 in at least 268 
three samples (frequency ≥2.8%) (Supplemental Table 4 [3]). The frequency of recurrent mutations 269 
previously described in ACC [8 9 31] and in our series is shown in Figure 1A. The most frequently 270 
mutated genes were: TP53 (22%), CTNNB1 (17%), NF1 (11%), APC (8.4%), ZNRF3 (8.4%), MEN1 271 
(7.4%), GNAS (6.5%) and ATRX (6.5%). We also discovered novel recurrent mutations not clearly 272 
associated with ACC yet, such as in NOTCH1, CIC, KDM6A, BRCA1 and BRCA2 (all ≥2.8%) (Figure 273 
1A and Supplemental Table 4 [3]).  274 
We then evaluated somatic CNVs in the same series. Most frequent CN gains were observed 275 
in CDK4 (43%), NOTCH1 (19%), TERT (12%), FGFR3 (12%) and MDM2 genes (7.4%) and CN 276 
losses at RB1 (5.6%), as expected (Figure 1B). The presence of amplifications at CDK4 locus was 277 
confirmed by FISH analysis (see Figure 2). We also found CN alterations that were not previously 278 
reported in ACC, such as gains in STK11 (31%), GNA11 (17%) and losses in TNFRSF14 (30%), 279 
SMARCB1 (22%), FLCN (20%) and CHEK2 (13%) (Figure 1B). 280 
Using our targeted sequencing approach, we identified three different CN patterns, consistent 281 
with a previous report [9]. Accordingly, we defined them as “chromosomal” when at least three large 282 
chromosomal regions were affected by amplifications or deletions, “quiet” when less than three 283 
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regions were altered and “noisy” when several small regions were affected (modified from [9]). An 284 
example of each CN pattern is reported in Supplemental Figure 3 [3]). 38 ACC samples were 285 
recognized to present a “chromosomal” pattern, 44 a “quiet” pattern and 25 a “noisy” pattern.  286 
The two most frequently affected pathways were p53/Rb signaling (59.8%; including 287 
alterations in CDKN2A, CDK4, MDM2, RB1 and TP53) and Wnt/β-catenin pathway (33.6%, including 288 
alterations in APC, CTNNB1, MED12, MEN1 and ZNRF3). In 22 of 107 samples (20.6%) both 289 
pathways were involved. 3 of these patients (2.8%) had variations in CTNNB1 and TP53. Another 290 
frequently altered pathway was the chromatin remodeling pathway (29.9%) (Fig 1C). In a lower 291 
percentage of cases, genetic variations in genes of the DNA repair (7.4%) or the mismatch repair 292 
(MMR) systems (4.5%) were observed (Figure 1C).  293 
The methylation pattern of promoter regions of four preselected genes was also evaluated. The 294 
median percentage of methylated promoter regions in the tumor material was 11% at PAX5 (range: 1-295 
98), 22% at PAX6 (range: 2-97), 17% at PYCARD (range: 1-94) and 3% at GSTP1 (range: 1-74). 296 
Considering all genes, the median value of mean methylation was 21% (range: 2-77). 33 tumors 297 
presented a promoter methylation status “high” (31% of cases).  298 
A high BUB1B-PINK1 differential expression is a known negative prognostic marker in ACC 299 
[10]. Thus, we evaluated BUB1B and PINK1 mRNA expression levels in a subgroup of 38 FFPE 300 
tumor specimens with good RNA quality (32.5%). The analysis of this series revealed a high BUB1B-301 
PINK1 differential expression in 16 cases (42%, Supplemental Figure 4). 302 
 303 
Prognostic stratification 304 
To evaluate the benefit of applying a molecular classification to prognosticate clinical outcome, we 305 
first investigated prognostic effectiveness of ENSAT tumor staging classification in our series. As 306 
expected, the median PFS was shorter for patients with metastatic disease (ENSAT 4, n=23) than for 307 
those with intermediate (ENSAT 3, n=28) or early tumor stages (ENSAT 1 to 2, n=58) (P<0.0001, 308 
chi-square=35.6, Figure 3A). However, using the mGRAS score (see Methods), we obtained an 309 
improved prognostic stratification by recognizing 4 subgroups with different clinical outcome, from 310 
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favorable prognosis (median PFS=54 months) to poor prognosis (median PFS=3 months) (P<0.0001, 311 
chi-square=49.0, Figure 3B). 312 
Considering the results of the targeted molecular analysis, five events predicted a shorter PFS 313 
in univariate analysis: 1. Presence of more than one mutation (P=0.0015, HR=2.12, 95%CI=1.3-3.4); 314 
2. Noisy CNA pattern (P=0.0038, HR=2.46, 95%CI=1.3-4.5); 3. Presence of alterations in Wnt/β-315 
catenin signaling alone or together with p53/Rb (P<0.0001); 4. Promoter methylation status “high” 316 
(P=0.0002, HR=2.9, 95%CI=1.7-5.0); 5. High BUB1B-PINK1 differential expression (n=38, 317 
P=0.0037, HR=2.56, 95%CI=1.16-5.67). To investigate the applicability of a molecular prognostic 318 
classification in a clinical setting, we developed a simplified score excluding parameters that cannot be 319 
reliably and easily analyzed by targeted analysis in FFPE samples (i.e. CNA pattern and mRNA 320 
expression). At multivariate analysis including clinical/histopathological parameters, presence of 321 
alterations at Wnt/β-catenin alone or with p53/Rb signaling and promoter methylation status “high” 322 
remained significant (P=0.026, HR=1.39, 95%CI=1.04-1.87, and P=0.003, HR=2.03, 95%CI=1.27-323 
3.25, respectively). We then combined genetic items in a molecular score as follows: number of 324 
somatic mutations (0-1=0 points, >1=1 point), alterations in the Wnt/β-catenin and p53/Rb pathways 325 
(none=0 points, only Wnt/β-catenin=1 point, Wnt/β-catenin+ p53/Rb=2 points) and promoter regions 326 
methylation pattern (≤25%=0 points, >25%=1 point) (overall points 0 to 4). This allowed us to 327 
separate four groups with PFS as endpoint: score 0 (n=35, median PFS=36 months), score 1 (n=30, 328 
median PFS=9 months), score 2 (n=22, median PFS=6 months) and score 3-4 (n=20, median PFS=4 329 
months) (P<0.0001, chi-square=34.4; for definition see Figure 3C).  330 
By merging mGRAS and molecular score into a combined (COMBI) score, we obtained a 331 
further improvement in the progression risk stratification. In particular, we better distinguished a 332 
group of patients with a really favorable prognosis (median PFS=54 months) and further three groups 333 
with good (median PFS=13 months), intermediate (median PFS=6 months) and poor prognosis 334 
(median PFS=3 months) (P<0.0001, chi-square=68.6; for definition see Figure 3D). When we tested 335 
the superiority of COMBI in respect to mGRAS score by discriminating patients with the best clinical 336 
outcome (at least 24 months free of disease progression), COMBI score showed a better prognostic 337 
performance, proven by superior specificity (58.6 vs 31.0%) and accuracy (83.3% vs 74.5%). 338 
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Moreover, the area under the ROC curve was higher for COMBI than for mGRAS score (0.872, 339 
95%CI=0.800-0.943, vs 0.780, 95%CI=0.689-0.871) (Supplemental Figure 5A-B [3]).  340 
A heatmap sorted for prognosis including mGRAS score, molecular parameters and COMBI 341 
score is shown in Figure 4. 342 
We then decided to compare the prognostic power of mGRAS and COMBI score evaluating 343 
the disease-free survival (DFS) in those 74 ACC patients that were successfully operated (R0). In this 344 
subgroup, only COMBI score was able to identify a category of patients with an extremely longer 345 
DFS: median DFS for COMBI 0-2 (n=23)=243 months, COMBI 3-4 (n=30)=13 months, COMBI 5-7 346 
(n=18)=5.5 months, COMBI 8-13 (n=3)=3 months  (P< 0.0001, Chi-Square 50.98, see Supplemental 347 
Figure 6).  348 
 349 
Prediction of response to therapy 350 
In patients treated with adjuvant mitotane (n=39), a low COMBI score (0-2) was slightly more 351 
powerful to predict a longer disease-free survival then a low mGRAS (0-1) (P=0.0001, chi-352 
square=21.5, vs P=0.0058, chi-square=12.5). However, similar results were obtained considering 353 
patients with superimposable disease stages that did not receive adjuvant mitotane (n=49) (COMBI 354 
score: P=0.0001, chi-square=27.5, mGRAS: P=0.0008, chi-square=16.8), thus suggesting no specific 355 
relationship between molecular alterations and response to mitotane. 356 
In patients with advanced ACC, none of the single molecular events showed a significant 357 
predictive role for response to mitotane monotherapy (n=34), EDP-M (n=52), gemcitabine plus 358 
capecitabine (n=36) and/or streptozotocin (n=44). These analyses were performed by considering both 359 
objective response to the investigated drugs and time to progression during treatment.  360 
 361 
Actionable molecular alterations 362 
Having chosen a NGS panel that includes several known pharmacologically targetable genetic 363 
alterations allowed us to directly look for their presence in ACC. According to the level of evidence 364 
(OncoKB website), we found at least one alteration in a drug targetable gene in 64 of our 107 patients. 365 
The list and specifics of 17 actionable genetic alterations are reported in Table 2. Most interesting 366 
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ones are CN gains at gene CDK4 (43% of cases) that are accessible by different CDK4/6 inhibitors 367 
already approved for other types of solid tumors. Moreover, recurrent alterations at NOTCH1, targeted 368 
by gamma secretase inhibitors, NF1, targeted by MEK inhibitors, or at MDM2, targeted by MDM2 369 
inhibitors, were recognized. Mutations in other known druggable genes, such as those coding for 370 
receptor tyrosine kinases (EGFR, KIT, and RET), members of the DNA repair system (ATM, BRCA1, 371 
and BRCA2), PTCH1 and TSC1/TSC2 were detected in a small percentage of samples (<3%). In two 372 
ACC samples we identified the well-known Val600Gly activating mutation in the gene BRAF, which 373 
is found in approximately 50% of papillary thyroid carcinomas and is directly actioned by BRAF 374 
and/or MEK inhibitors. Finally, mutations and/or CN losses were also observed in MMR genes 375 
MLH1, MSH2, and MSH6, which are associated with response to immune checkpoint inhibitors such 376 
as PD1/PDL1 inhibitors. 377 
 378 
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Discussion 379 
The present study represents the largest study combining targeted NGS and methylation analysis on 380 
ACC samples (n=117) using FFPE tissue specimens that are easily obtainable during routine 381 
histopathological workup. Our results clearly demonstrate that these analyses are feasible on FFPE 382 
material. Furthermore, we propose a new combined histological, clinical, and molecular score that 383 
improves the prognostic stratification in this rare disease (COMBI score). Finally, we identify 384 
actionable molecular events in 60% of patients.  385 
Interestingly, we could evaluate the genetic profile of consecutive tumors from 10 patients. In 386 
these cases, we found a good concordance between primary and recurrent tumors in terms of both 387 
TMB and mutated genes, similarly to what is described for other cancer types [37]. Thus, we 388 
considered only the first available tumor sample for each single patient (n=107). Overall, we 389 
confirmed the presence of frequent ACC-associated alterations (Figure 1A). Notably, we also detected 390 
in a smaller percentage of cases alterations previously not clearly associated with ACC (>2.5%, i.e. 391 
mutations at NOTCH1, CIC, and BRCA1/2, amplifications in STK11, GNA11 and deletions in 392 
TNFRSF14, SMARCB1). In terms of signaling pathways, the most frequently involved were p53/Rb 393 
and Wnt/β-catenin, as expected. In 22 samples (20.6%) we observed alterations in both signaling 394 
pathways representing an important negative prognostic marker - a. A rate that was already reported in 395 
literature [8 9]. In the group with worst prognosis also 3 patients (2.8%) with alterations in CTNNB1 396 
and TP53 were observed. While Ragazzon et al. found alterations in CTNNB1 and TP53 mutually 397 
exclusive, a small number of patients in the cohort of Assié et al. and Zheng et al. had variants in both 398 
genes, thus also supporting our data. We also found alterations in genes involved in chromatin 399 
remodeling, as expected [8 9 31 38]. More surprisingly, we also observed recurrent genetic alterations 400 
affecting members of the MMR (i.e. MLH1, MSH2, MSH6) or homologous recombination DNA repair 401 
system (i.e. ATM, BRCA1, BRCA2).  402 
Concerning the prognostic role of molecular markers, we could confirm in our FFPE series the 403 
impact of already proposed molecular markers already proposed in studies on fresh-frozen material [8 404 
9 31]. However, the investigation of the CN pattern was not easily achievable starting from targeted 405 
analysis in FFPE material. Similarly, the isolation of high quality RNA from FFPE tissue was 406 
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successful in only 32.5% of samples, allowing investigation of mRNA expression in only a subset of 407 
patients. Therefore, we excluded these markers from further analysis. A simplified molecular 408 
prognostic score was then devised which includes mutational load, alterations in p53/Rb and Wnt/β-409 
catenin pathway and promoter methylation status “high”. However, importantly, only by merging 410 
molecular alterations with clinical/histopathological parameters included in mGRAS into a COMBI 411 
score, we obtained the best discrimination among ACC patients with different prognostication. 412 
COMBI score was particularly supportive to identify patients with an extremely favorable clinical 413 
outcome, showing the best predictive accuracy for discriminating patients without disease 414 
recurrence/progress within the first 24 months after primary surgery when compared to mGRAS score. 415 
The superiority of COMBI score was even more evident when considering the capability to predict 416 
DFS in patients successfully operated. These findings might play a key role in clinical practice, 417 
helping to better select patients that do not need aggressive treatment, thus sparing unnecessary side 418 
effects to patients and costs for the community.  419 
A targeted approach to molecular analysis has been recently proposed by Assie and colleagues 420 
[39], who validated targeted NGS for calling simultaneously mutations, chromosome alterations and 421 
DNA methylation status. Such analysis might have clinical benefits, but still needs to be validated in 422 
FFPE material. Considering other cancer types, genetic analysis by targeted NGS and methylation 423 
analysis by pyrosequencing have been performed in FFPE tumour specimens obtaining good results 424 
[40-42]. Nevertheless, this kind of approach had not been tested in ACC samples until now. In general, 425 
it is now the task to prove that proposed molecular-driven scores are clinically helpful to guide 426 
clinicians in patient care. To this end, only a multicenter, prospective and randomized trial will 427 
provide reliable answers, but the international ACC community seems to be well connected to perform 428 
such effort.  429 
Furthermore, we intended to investigate the potential predictive role of molecular alterations 430 
for response to systemic chemotherapies. However, none of the evaluated alterations were associated 431 
with the response to any standard pharmacological therapy in ACC. This might have different 432 
explanations, including the heterogeneity of treatments usually used in this kind of patients and the 433 
complexity of the molecular background of ACC. 434 
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Finally, we intended to identify potentially druggable molecular events. A similar approach 435 
has been used in few previous studies in small series of patients (up to 40) demonstrating the presence 436 
of potentially actionable genomic alterations in a subset of ACC [19 20]. In our study, we concentrated 437 
on molecular events targeted by drugs already available for solid tumors (OncoKB). Based on our 438 
analysis, the most promising candidate is the gene CDK4. Specifically, CN gains at the CDK4 locus 439 
are already reported in the literature on ACC [8 19 20], but we observed them in an even higher 440 
percentage of cases (>40%). These alterations were confirmed with FISH analysis. Our findings may 441 
be clinically relevant because selective CDK4/6 inhibitors palbociclib and ribociclib have been 442 
approved by FDA for treatment of breast cancer [43]. Phase I-III studies are now ongoing with other 443 
CDK4/6 inhibitors in solid tumors (https://clinicaltrials.gov/) [44]. Moreover, although they have not 444 
been tested in ACC patients yet, CDK4/6 inhibitors have been shown to reduce cell viability in ACC 445 
cell lines [45 46].  446 
Another promising drug target is NOTCH1 gene, which was gained in >20% of cases in 447 
present series and in >40% in a previous study [47]. Notch pathway might represent an interesting 448 
target as it was reported to be activated in ACC [48] and can be actioned by different gamma secretase 449 
inhibitors (GSI) or monoclonal antibodies [49]. For instance, the GSI PF-03084014 has already been 450 
tested in Phase I study in patients with advanced solid tumors [50]. Presence of copy number gains at 451 
MDM2 (7% of cases) might also be considered encouraging targets as MDM2 inhibitors such as DS-452 
3032b or RG7112 have been reported to reduce cell proliferation in MDM-amplified liposarcoma [51]. 453 
An interesting therapeutic option is also represented by targeting the BRCA-related DNA repair 454 
system (altered in >7% of cases) by PARP inhibitors (i.e. olaparib, nirapanib and rucaparib) [52] that 455 
are approved for treatment of BRCA-mutant ovarian. Moreover, mutations in targetable genes coding 456 
for receptor tyrosine kinases (EGFR, KIT, RET), members of mTOR pathway (TSC1/2) and BRAF 457 
were detected in rare cases. Finally, in 4.5% of cases, we observed mutations or CN losses in members 458 
of the MMR system (MSH2, MSH6, MLH1), which have been reported as predictive biomarkers for 459 
antitumor effects of checkpoint PD1/PDL1 inhibitors (i.e. pembrolizumab or novolumab [53 54]). Our 460 
findings on actionable targets open up new therapeutic avenue for subsets of ACC patients.  461 
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In conclusion, our study demonstrates that molecular classification based on targeted genetic analysis 462 
is able to improve the prognostication of ACC patients when combined with clinical/histopathological 463 
parameters. This approach paves the way to a personalized management of ACC, allowing better 464 
decisions about need for adjuvant therapies and/or frequency of periodical post-operative monitoring. 465 
Additionally, our targeted panel can at the same time identify druggable targets. In some cases, these 466 
results may be used to select patients for clinical trials or off-label use of specific anti-cancer drugs. 467 
The fact that all this is possible in readily available FFPE material is a major step towards precision 468 
medicine in this rare disease.  469 
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Legend to figures 641 
 642 
Figure 1. Recurrent genetic alterations observed by targeted next generation sequencing and 643 
Sanger sequencing (ZNRF3) in adrenocortical carcinoma. A) Somatic protein-altering mutations 644 
detected in the present series of FFPE tumors (n=107) and in the series of snap-frozen tumors 645 
available in the literature (n=182); B) Copy number (CN) alterations (gains and losses) detected in the 646 
present series of FFPE tumors (n=107). Heterozygosis=duplicated with a fold change between 1.25 647 
and 1.75, homozygosis=duplicated with a fold change > 1.75. C) Altered signaling pathways identified 648 
by curated analysis. Alterations are defined by somatic mutations and copy number gains or losses. 649 
 650 
Figure 2. Example of CDK4 copy number (CN) gains.  A) CN analysis by targeted next generation 651 
sequencing in one FFPE tumor slide with homozygous CDK4 amplification (view of all genes covered 652 
in the panel); B) zoom view of the CDK4 locus at chr. 12); and C) validation by FISH analysis in the 653 
same FFPE tumor slide (Dual Color Probe: CDK4 in green and CEN12 in red). D) CN analysis by 654 
targeted next generation sequencing in one FFPE tumor slide with homozygous CDK4 amplification 655 
(view of all genes covered in the panel); E) zoom view of the CDK4 locus at chr. 12); and F) 656 
validation by FISH analysis, respectively. G) CN analysis by targeted next generation sequencing in 657 
one FFPE tumor slide without CDK4 amplification (view of all genes covered in the panel); H) zoom 658 
view of the CDK4 locus at chr. 12); and I) validation by FISH analysis, respectively. 659 
 660 
Figure 3. Prognostication of clinical outcome (progression-free survival) in 107 patients with 661 
adrenocortical carcinoma according to different parameters. A) Initial ENSAT tumor stage (1 to 662 
4); B) Modified GRAS score including ENSAT tumor stage (1 or 2=0, 3=1, 4=2), Ki67 index (0-9=0, 663 
10-19=1, ≥20=2), R status (R0=0, RX=1, R1=2, R2=3), age (<50 years=0, ≥50 years=1) and 664 
symptoms (no=0, yes=1) (overall points 0-9); C) Molecular score including number of somatic 665 
mutations (0-1=0, >1=1), alterations in the Wnt/β-catenin and p53/Rb pathways (none=0, only Wnt/β-666 
catenin=1, Wnt/β-catenin+ p53/Rb=2) and promoter regions methylation pattern (≤25%=0, >25%=1) 667 
(overall points 0 to 4); D) COMBI score including mGRAS and molecular score (overall points 0 to 668 
13). 669 
Lippert et al., 26 
 
Figure 4. Heatmap representing the clinical outcome of the 107 patients with adrenocortical 670 
carcinoma in relationship with the evaluated clinical/histopathological score (mGRAS), the most 671 
relevant and “easy-to-apply” molecular parameters and the calculated COMBI score. Patients 672 
are subdivided into four different “prognosis” subgroups according to PFS: favorable prognosis by 673 
PFS >24 months (n=29), good prognosis by PFS 12-24 months (n=13), intermediate prognosis by PFS 674 
6-11 months (n=20) and bad prognosis by PFS <6 months (n=40). The remaining 5 patients who were 675 
still alive at the last follow up were considered as “not applicable” in terms of prognosis classification 676 
because of an insufficient time-span of follow up. 677 
 678 
Legend to Tables 679 
 680 
Table 1. Baseline clinical/histopathological characteristics of 107 patients with adrenocortical 681 
carcinoma included in the study.  682 
 683 
Table 2. Potential drug targets identified by next-generation sequencing in 107 patients with 684 
adrenocortical carcinomas. 685 
 686 
Table 1. Baseline clinical/histopathological characteristics of 107 patients with adrenocortical 
carcinoma included in the study.  
Parameter  
N 107 
Sex (M/F) 46/61 
Baseline (at time of diagnosis)  
Age – yrs (median, range) 
- <50 years – n (%) 
- ≥50 years – n (%) 
49 (18-87) 
57 (53.3) 
50 (46.7) 
Clinical presentation (available data) 
- Incidentally – n (%) 
- Tumor-related – n (%) 
- Hormone-related – n (%) 
107 
31 (29.0) 
45 (42.0) 
31 (29.0) 
Hormone secretion (available data) 
- Glucocorticoids alone – n (%) 
- Mixed secretion – n (%) 
- Endocrine inactive – n (%) 
- Others (androgens, mineralcorticoids, estrogens) – n (%) 
- Unknown – n 
81 
24 (29.6) 
25 (30.8) 
25 (30.8) 
7 (8.6) 
26 
Initial ENSAT tumor stage (available data) 
  1-2 – n (%) 
  3 – n (%) 
  4 (metastatic) – n (%) 
107 
56 (52.3) 
28 (26.2) 
23 (21.5) 
Resection status (available data) 
  R0 – n (%) 
  RX – n (%) 
  R1 – n (%) 
  R2 – n (%) 
  Unknown - n 
104 
74 (71.1) 
16 (15.4) 
5 (4.8) 
9 (8.6) 
3 
Ki67 proliferation index (median, range) 
- 0-9 – n (%) 
- 10-19 - n (%) 
- ≥20 – n (%) 
12 (1-90) 
31 (29.0) 
33 (30.8) 
43 (40.2) 
Type of tumor 
  Primary – n (%) 
  Local recurrence – n (%) 
  Metastasis – n (%) 
 
89 (83.2) 
9 (8.4) 
9 (8.4) 
During follow up  
Duration of follow up – months (median, range) 
Deaths – n (%) 
31 (3-274) 
54 (50.5) 
Local therapeutic approaches 
Additional surgeries – n (%) 
   Radiotherapy (tumor bed or metastasis) – n (%) 
   Iodometomidate – n (%) 
 
26 (24.3) 
19 (17.8) 
7 (6.5) 
Mitotane 
   Adjuvant setting – n (%) 
   Palliative setting – n (%) 
73 (68.2) 
39 (36.4) 
34 (31.8) 
Cytotoxic chemotherapies  
   None – n (%) 
   Platinum-compounds – n (%) 
   Streptozotocin – n (%) 
   Gemcitabin plus Capecitabin – n (%) 
 
45 (42.1) 
52 (48.6) 
44 (41.1) 
36 (33.6) 
Abbreviations: F=female; M=male; n=number of patients; n.a= not available; ns=not significant; R0=complete 
resection; R1=microscopic incomplete resection; R2=macroscopic incomplete resection; RX=uncertain 
resection; yrs=years. 
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Table 2. Potential drug targets identified by next-generation sequencing in 107 patients with 
adrenocortical carcinomas. 
Gene  
symbol 
Description  Type of observed 
alteration  
% 
samples 
Potential targeted therapy Level of 
evidenceA 
DNA level     
CDK4 Cyclin 
dependent 
kinase 
CN gains 
 
Missense mutation 
43 
 
1.8 
CDK4/6 inhibitor 
(palbociclib/abemaciclib/ 
ribociclib) 
2A 
(liposarcoma) 
NOTCH1 NOTCH 
signaling 
CN gains 
 
Missense mutation 
20.5 
 
4.7 
Gamma secretase inhibitor 
(PF-03084014) 
4 (all tumours) 
NF1 RAS/MAPK 
regulation 
Del/Dup or 
missense mutation  
11.2 MEK inhibitor 
(trametinib/cobimetinib) 
4 (glioblastoma 
/melanoma)B 
MDM2 P53 pathway CN gain 7.0 MDM2 inhibitors  
(DS-3032b, RG7112) 
3A 
(liposarcoma) 
EGFR Receptor 
tyrosin 
kinase  
Missense mutation 
 
2.8 TKI 
(afatinib/erlotinib,/gefitinib) 
1 (NSCLC)B 
BRCA1 
 
BRCA2 
DNA repair 
system  
Del or missense 
mutation 
Missense mutation 
2.8 
 
2.8 
PARP inhibitor 
(rucaparib/olaparib/nirapanib) 
(synthetic lethality) 
1-2A  
(ovary ca)B 
ATM DNA repair 
system 
Missense mutation 
or delins 
1.8 PARP inhibitor (olaparib) 
(synthetic lethality) 
4 (prostate ca)B 
BRAF Ser/thr kinase  Missense mutation 1.8 BRAF inhibitor 
(vemurafenib/dabrafenib) 
MEK inhibitor 
(trametinib/cobimetinib) 
1 (cutaneous 
melanoma) 
2A (NCSLC) 
4 (thyroid ca) 
PTCH1 Sonic 
hedgehog 
receptor  
Missense mutation 1.8 Hedgehog inhibitor 
(sonidegib) 
 
3A (skin ca)B 
TSC1 
 
TSC2 
mTOR 
pathway  
Del (frameshift) 
Missense mutation 
Missense mutation 
1.8 
 
0.9 
mTOR inhibitor (everolimus) 2A (CNS + 
renal ca)B 
KIT Receptor 
tyrosin 
kinase  
Missense mutation  
 
0.9 
 
TKI (imatinib/sunitinib) 1 (GIST)B 
2A (melanoma) 
RET Receptor 
tyrosin 
kinase  
Missense mutation  0.9 TKI (cabozantinib) 
 
2A (NSCLC)B 
ESR1 Estrogen 
receptor 
Missense mutation  0.9 AZD9496 (fulvestrant) 3A (breast ca)B 
EZH2 Histone N-
methyl-
trasferase  
Nonsense 
mutation  
0.9 GSK126 (tazemetostat) 4 (B-cell 
lymphoma)B 
Abbreviations: CN=copy number; NCSLC=non-small cell lung cancer; TKI=tyrosine kinase inhibitor.  
AEvidence by OncoKB website (http://oncokb.org/#/, (21)): Level 1=FDA-approved biomarker; Level 2A= 
standard care biomarker in this indication; Level 2B: Standard care biomarker in another indication, Level 3A= 
predictive biomarker according to clinical evidence in this indication; Level 3B= predictive biomarker according 
to clinical evidence in another indication Level 4= predictive biomarker according to biological evidence. Bnot 
the same molecular alteration. 
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A)                                                                          
B)
C)                                                                          
Inhibition   Activation
 p53/Rb1 signaling
59.8% of cases altered
CDKN2A
0%
MDM2
7.6%
Amplified 43 %,  
mutated 1.8 %
Cell cycle progression
CDK4
44.8%
RB1
 9.9%
TP53
22.4%
Mutated
Amplified
Deleted NA,  
mutated 0 %
Deleted 5.2 %,  
mutated 4.7 %
 Wnt/beta catenin
33.6% of cases altered
CTNNB1
16.8%
APC
8.4%
Cell cycle progression
ZNRF3
8.4%
Deleted NA,  
mutated 8.4 %
Mutated
Mutated
MEN1
7.4%
Mutated                  Mutated
 DNA mismatch repair
4.5% of cases altered
MLH1
1.8%
Mutated
MSH2
1.8%
Mutated
Mutated
MSH6
0.9%
DNA damage response/
genomic stability
 Chromatin remodelling
29.9% of cases altered
ATRX
6.5%
DAXX
4.7%
KDM6A
2.8%
SETD2
1.8%
KMT2D
1.8%
DNMT3A
1.8%
TERT
12.4%
Mutated                  Mutated
Mutated                  Mutated
Amplified                Mutated
 BRCA-DNA repair
7.4% of cases altered
ATM
1.8%
Mutated
BRCA1
2.8%
Mutated
Mutated
BRCA2
2.8%
DNA damage response/
genomic stability
 NOTCH-Signalling
27.1% of cases altered
FBXW7
1.9%
Mutated
NOTCH1
25.2%
Amplified 20.5%,
mutated 4.7 %
Cell-cell communication
Inactivated                                 Activated   
Percentage of Cases (%)
50                                0                                  50
Variable  
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Prognosis
mGRAS Score
COMBI Score
Number of Mutations
Wnt/p53 Pathway
Methylation
CNA Pattern
BUB1B-PINK1
Legend:
Prognosis:                                        bad                      intermediate       good                   best                    not applicable
mGRAS Score:                                 0-1                     2-3                      4-5                     6-8
COMBI Score:                                  0-2                      3-4                      5-7                      >7
Number of Mutations:                       0-1                      2-4                     >4
Wnt/p53 Pathway:                            none                  Wnt only             Wnt and p53
Methylation:                                      <= 25 %              > 25 % 
CNA Pattern:                                    noisy                   chromosomal/quiet
BUB1B-PINK1:                                 <= 6.3                >6.3                    not available             
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